Mycamine 2015 report
Mycamine 2015 U.S. PROMOTIONAL AUDIT REPORT
Published July 2016 • 27 Pages
The 5 Key Questions Addressed by this Report:
- How many physicians were reached by Mycamine through personal promotion in 2015 and how does this compare to its peer set in the Candidiasis market?
- What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
- How does Astellas’s depth of coverage vary within key specialties (e.g., Infectious Disease, Internal Medicine, Pulmonology, Critical Care Medicine, and Family Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
- How often are physicians receiving paid meals for Mycamine throughout the year (e.g., monthly, quarterly, annually)?
- Who were the most detailed prescribers and top paid speakers/consultants for Mycamine in 2015?
Data Sources and Methodology:
- MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
- Over 5,200 paid interactions across 2,600 physicians made on behalf of Mycamine were carefully examined to support our analysis. In addition, interaction data from 1 peer products (e.g. Noxafil) was leveraged to provide benchmarking and market insights.